Published in MAbs on January 01, 2015
The making of bispecific antibodies. MAbs (2017) 0.84
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget (2016) 0.79
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs (2016) 0.78
Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion. MAbs (2016) 0.76
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep (2017) 0.75
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem (2016) 0.75
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Potent antibody therapeutics by design. Nat Rev Immunol (2006) 4.87
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem (2008) 1.88
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol (1992) 1.58
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 1.53
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med (2011) 1.49
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem (2005) 1.41
Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin (2005) 1.32
Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther (2010) 1.26
Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol (1995) 1.24
The future of antibodies as cancer drugs. Drug Discov Today (2012) 1.23
Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm (2009) 1.16
Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure (2010) 1.15
Antibodies to watch in 2014. MAbs (2013) 1.14
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer (2008) 1.12
Specificity in cancer immunotherapy. Semin Immunol (2008) 1.11
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs (2012) 0.97
Alternative antibody formats. Curr Opin Mol Ther (2010) 0.96
A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett (1998) 0.96
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
The tomato homolog of CORONATINE-INSENSITIVE1 is required for the maternal control of seed maturation, jasmonate-signaled defense responses, and glandular trichome development. Plant Cell (2003) 3.51
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood (2007) 3.33
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 2.54
Assessment of display performance for medical imaging systems: executive summary of AAPM TG18 report. Med Phys (2005) 2.23
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
An exposure indicator for digital radiography: AAPM Task Group 116 (executive summary). Med Phys (2009) 2.00
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res (2011) 1.78
Rose scent: genomics approach to discovering novel floral fragrance-related genes. Plant Cell (2002) 1.76
Metabolic, genomic, and biochemical analyses of glandular trichomes from the wild tomato species Lycopersicon hirsutum identify a key enzyme in the biosynthesis of methylketones. Plant Cell (2005) 1.59
Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl (2012) 1.49
O-methyltransferases involved in the biosynthesis of volatile phenolic derivatives in rose petals. Plant Physiol (2002) 1.44
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol (2008) 1.34
Bardet-Biedl syndrome-associated small GTPase ARL6 (BBS3) functions at or near the ciliary gate and modulates Wnt signaling. J Biol Chem (2010) 1.28
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol (2006) 1.25
Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr (2008) 1.24
Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol (2009) 1.19
Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.16
RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med (2013) 1.15
Intramolecular proton transfer in channelrhodopsins. Biophys J (2013) 1.14
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther (2010) 1.09
Deletions in the transmembrane domain of a sindbis virus glycoprotein alter virus infectivity, stability, and host range. J Virol (2003) 1.07
Timed efficiency of interpretation of digital and film-screen screening mammograms. AJR Am J Roentgenol (2009) 1.05
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs (2015) 1.04
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
Why does it take longer to read digital than film-screen screening mammograms? A partial explanation. J Digit Imaging (2009) 0.99
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol (2011) 0.97
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
Diffusion weighted imaging in prostate cancer. Eur Radiol (2010) 0.95
Attractant and repellent signaling conformers of sensory rhodopsin-transducer complexes. Biochemistry (2010) 0.92
The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One (2012) 0.91
Enhancement of the long-wavelength sensitivity of optogenetic microbial rhodopsins by 3,4-dehydroretinal. Biochemistry (2012) 0.90
The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation. J Neuroinflammation (2012) 0.90
Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther (2013) 0.89
Antibody humanization by framework shuffling. Methods (2005) 0.87
Automated method for accurate abdominal fat quantification on water-saturated magnetic resonance images. J Magn Reson Imaging (2007) 0.87
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-alpha toxin antibody fragment and alpha toxin. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.86
CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol (2014) 0.85
Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J Mol Biol (2011) 0.84
Tailor-made antibody therapeutics. Methods (2005) 0.84
Characterization, phylogenetic analysis and cDNA cloning of natterin-like gene from the blood of lamprey, Lampetra japonica. Immunol Lett (2012) 0.83
Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing. Virus Genes (2010) 0.83
Neonatal nicotine exposure impairs development of auditory temporal processing. Hear Res (2008) 0.82
Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.82
Prion protein participates in the regulation of classical and alternative activation of BV2 microglia. J Neurochem (2012) 0.81
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. MAbs (2015) 0.81
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol (2007) 0.81
Evaluation of stretched electrospun silk fibroin matrices seeded with urothelial cells for urethra reconstruction. J Surg Res (2013) 0.81
Novel translationally controlled tumor protein homologue in the buccal gland secretion of Lampetra japonica. Biochimie (2008) 0.80
Water-saturated three-dimensional balanced steady-state free precession for fast abdominal fat quantification. J Magn Reson Imaging (2005) 0.80
Using a gradient plot of luminance response curve as a metric for assessing and comparing softcopy display system quality. Med Phys (2006) 0.79
Novel biopolymers to enhance endothelialisation of intra-vascular devices. Adv Healthc Mater (2012) 0.78
The Candida albicans plasma membrane protein Rch1p, a member of the vertebrate SLC10 carrier family, is a novel regulator of cytosolic Ca2+ homoeostasis. Biochem J (2012) 0.78
Humanized antibodies and their applications. Methods (2005) 0.78
Novel rapid fat suppression strategy with spectrally selective pulses. Magn Reson Med (2005) 0.78
Targeting random mutations to hotspots in antibody variable domains for affinity improvement. Methods Mol Biol (2002) 0.78
C-Abl tyrosine kinase mediates neurotoxic prion peptide-induced neuronal apoptosis via regulating mitochondrial homeostasis. Mol Neurobiol (2014) 0.78
Low concentrations of the recombinant toxin protein rLj-RGD3 suppress TNF-α-induced human renal carcinoma cell invasion. Acta Biochim Biophys Sin (Shanghai) (2013) 0.77
A mammalian expression system for high throughput antibody screening. J Immunol Methods (2013) 0.77
Targeting the junction of CɛmX and ɛ-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol (2012) 0.77
Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies. Mol Immunol (2004) 0.76
The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts. Immunology (2015) 0.76
Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.76
Stereoscopic visualization of diffusion tensor imaging data: a comparative survey of visualization techniques. Radiol Res Pract (2013) 0.75
Human contrast-detail performance with declining contrast. Med Phys (2012) 0.75
Inhibition of phagocytosis reduced the classical activation of BV2 microglia induced by amyloidogenic fragments of beta-amyloid and prion proteins. Acta Biochim Biophys Sin (Shanghai) (2013) 0.75
A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments. Biomacromolecules (2016) 0.75
Isolation of nitrobenzene degrading strain Pseudomonas NB001 and application in the bioremediation of polluted water body. J Environ Sci Health A Tox Hazard Subst Environ Eng (2012) 0.75
[Expression and bioactivity effects to Hela of recombinant toxin protein rLj-RGD3 from Lampetra japonica]. Sheng Wu Gong Cheng Xue Bao (2009) 0.75
Effects of the recombinant toxin protein rLj-RGD3 in multidrug-resistant human breast carcinoma cells. Acta Biochim Biophys Sin (Shanghai) (2012) 0.75
[Expression of connective tissue growth factor in sciatic nerve after chronic compression injury and effect of rhodiola sachalinensis on its expression]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2014) 0.75
Analytical direct solutions of the Risley prism systems for tracking and pointing. Appl Opt (2014) 0.75
[Qijie theory of LAI's Tongyuan acupuncture technique]. Zhongguo Zhen Jiu (2016) 0.75
First evidence of protein G-binding protein in the most primitive vertebrate: serum lectin from lamprey (Lampetra japonica). Dev Comp Immunol (2013) 0.75